Chemical Peels for the Treatment of Melasma in Patients of Color
The study’s goal was to compare the clinical efficacy, safety, tolerability, and improvement in QOL index of three peeling agents for patients with melasma.
The study’s goal was to compare the clinical efficacy, safety, tolerability, and improvement in QOL index of three peeling agents for patients with melasma.
The prevalence and patterns of cutaneous manifestations in COVID-19 in patients with skin of color is reported.
Adjusted excess all-cause mortality in April 2020 varied by race/ethnicity and by state.
A summary of tips for capturing high quality images of patients with skin of color is provided.
The differences in incidence, clinical features, genetics, treatment and outcome, in cutaneous melanoma in White vs people of African descent populations is reviewed.
Mental health conditions and substance use are common during the COVID-19 pandemic, especially among racial- and ethnic-minority groups.
Data surrounding the association of UV exposure and risk for cutaneous melanoma in patients with skin of color was assessed.
The pressing need to clarify risk factors and effective interventions for skin of color populations is underscored.
Recent studies regarding therapeutic strategies to treat children with vitiligo are reviewed.
The efficacy of treatment with apremilast plus NB-UVB compared with NB_UVB alone in skin phototypes IV through VI with vitiligo were evaluated.